This is a news story, published by Yahoo, that relates primarily to Duchenne news.
For more Duchenne news, you can click here:
more Duchenne newsFor more disease research news, you can click here:
more disease research newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
muscular dystrophy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Duchenne patients news, FDA news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
gene therapyReuters
•82% Informative
U.S. Food and Drug Administration allows use of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy.
FDA gave traditional approval to patients four years and above who can walk, as well as accelerated approval for those who cannot.
Company added that the therapy should not be used in patients with certain mutations in DMD gene.
VR Score
92
Informative language
97
Neutral language
88
Article tone
formal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links